SCHEMBL303315

SCHEMBL303315

CCCCCCCCCCCCCCCN(C)C=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 3/20 0.52
ADH1C P00326 2/20 0.50
ADH1A P07327 2/20 0.50
ADH4 P08319 2/20 0.50
TSHR P16473 2/20 0.44
EPHX1 P07099 1/20 0.41
ADH1B P00325 1/20 0.41
ADH7 P40394 1/20 0.41
S1PR2 O95136 1/20 0.41
S1PR1 P21453 1/20 0.41
S1PR3 Q99500 1/20 0.41
S1PR5 Q9H228 1/20 0.41
THRB P10828 1/20 0.40
FAAH O00519 2/20 0.39
TRPV1 Q8NER1 1/20 0.39
GGPS1 O95749 3/20 0.38
EPHX2 P34913 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL77300 1.00 DNM1 (0.52) DNM1ADH1CADH1AADH4TSHR
SCHEMBL11077987 1.00 DNM1 (0.52) DNM1ADH1CADH1AADH4TSHR
SCHEMBL1721710 1.00 DNM1 (0.52) DNM1ADH1CADH1AADH4TSHR
SCHEMBL303397 1.00 DNM1 (0.52) DNM1ADH1CADH1AADH4TSHR
SCHEMBL6152969 1.00 DNM1 (0.52) DNM1ADH1CADH1AADH4TSHR
SCHEMBL303801 1.00 DNM1 (0.52) DNM1ADH1CADH1AADH4TSHR
SCHEMBL9660379 1.00 DNM1 (0.52) DNM1ADH1CADH1AADH4TSHR
SCHEMBL1061739 1.00 DNM1 (0.52) DNM1ADH1CADH1AADH4TSHR
SCHEMBL303288 1.00 DNM1 (0.52) DNM1ADH1CADH1AADH4TSHR
SCHEMBL11078053 1.00 DNM1 (0.52) DNM1ADH1CADH1AADH4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2852581-B1 NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS WOLFF AUGUST GMBH & CO KG ARZNEIMITTEL DR (DE) 2016-05-04 EP disclosed
US-9255070-B2 Method of deuteration using mixed catalyst WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2016-02-09 US disclosed
US-8093422-B2 Method for deuteration of an aromatic ring WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2012-01-10 US disclosed
US-7517990-B2 Method for deuteration of a heterocyclic ring WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2009-04-14 US disclosed
US-20080234488-A1 Method of Deuteration Using Mixed Catalyst WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2008-09-25 US disclosed
US-20070255076-A1 Method for Deuteration of an Aromatic Ring WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2007-11-01 US disclosed
EP-1707548-A1 METHOD OF DEUTERATION USING MIXED CATALYST Wako Pure Chemical Industries, Ltd. (JP) 2006-10-04 EP disclosed
US-20060116535-A1 Method of deuteration WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2006-06-01 US disclosed
US-20060025596-A1 Method for deuteration or tritiation of heterocyclic ring FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2006-02-02 US disclosed
EP-1577280-A1 METHOD OF DEUTERIZATION Wako Pure Chemical Industries, Ltd. (JP) 2005-09-21 EP disclosed
EP-1561741-A1 METHOD FOR DEUTERATION OR TRITIATION OF HETEROCYCLIC RING Wako Pure Chemical Industries, Ltd. (JP) 2005-08-10 EP disclosed
EP-1535889-A1 METHOD OF DEUTERATING AROMATIC RING Wako Pure Chemical Industries, Ltd. (JP) 2005-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025596-A1 Method for deuteration or tritiation of heterocyclic ring HRH2, HRH4, HDHD5 DNM1 1439/4885ADH1C 715/4885ADH1A 960/4885
US-20080234488-A1 Method of Deuteration Using Mixed Catalyst HDHD5, DHX35, HRH3 DNM1 162/4885ADH1C 1044/4885ADH1A 1333/4885
US-20070255076-A1 Method for Deuteration of an Aromatic Ring HRH3, HRH4, AHR DNM1 563/4885ADH1C 1127/4885ADH1A 823/4885
US-20060116535-A1 Method of deuteration ARL1, IDH2, IDH3A DNM1 1158/4885ADH1C 186/4885ADH1A 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.